Participated · Series A · May 2022

Fairtility provides an Embryo Quality Assessment Assistant that applies transparent AI to IVF decision-making, giving clinicians and patients visibility into the biological data informing embryo assessments. CHLOE EQ™ (Cultivating Human Life through Optimal Embryos) produces data intended to support IVF professionals' experience and intuition by leveraging the collective analysis of millions of data points collected from diverse embryology labs and workflows globally. The company plans to use the new funding to advance clinical research with fertility clinics and academic institutions worldwide and to support regulatory approval processes. Fairtility also intends to develop CHLOE beyond embryo assessment to span the full breadth of IVF treatment. Led by co-founder and CEO Eran Eshed and based in Tel Aviv, Israel, the company has raised $18.5M in total funding to date.